Beyondspring Inc
NASDAQ:BYSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beyondspring Inc
NASDAQ:BYSI
|
US |
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
CN |
|
Dongbang Agro Corp
KRX:007590
|
KR |
|
V
|
Vikas WSP Ltd
BSE:519307
|
IN |
|
Anhui Jianghuai Automobile Group Corp Ltd
SSE:600418
|
CN |
|
Jenoptik AG
XETRA:JEN
|
DE |
|
J
|
Jainco Projects (India) Ltd
BSE:526865
|
IN |
|
LG Energy Solution Ltd
KRX:373220
|
KR |
|
Cordlife Group Ltd
SGX:P8A
|
SG |
|
Fundamenta Real Estate AG
SIX:FREN
|
CH |
|
T
|
Thong Nhat Rubber JSC
VN:TNC
|
VN |
|
M
|
Mercor SA
WSE:MCR
|
PL |
|
China Foods Ltd
HKEX:506
|
HK |
|
J
|
Jiangsu Jinji Industrial Co Ltd
SZSE:300798
|
CN |
|
Cango Inc
NYSE:CANG
|
CN |
|
Capital & Counties Properties PLC
LSE:CAPC
|
UK |
|
Titan Biotech Ltd
BSE:524717
|
IN |
|
B
|
BLS Infotech Ltd
BSE:531175
|
IN |
|
Z
|
Zhejiang Zhengte Co Ltd
SZSE:001238
|
CN |
|
H
|
Hamelin Gold Ltd
ASX:HMG
|
AU |
|
Korea Engineering Consultants Corp
KRX:023350
|
KR |
|
S
|
Shandong Ruifeng Chemical Co Ltd
SZSE:300243
|
CN |
|
PPK Group Ltd
ASX:PPK
|
AU |
|
M
|
Muramoto Electron Thailand PCL
SET:METCO
|
TH |
Beyondspring Inc
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
